NBTX Nanobiotix Corp: Earnings per one share for the last 12 months

Official company branding of Nanobiotix SA (NBTX)

The development of Nanobiotix S.A. (NBTX) is tied to regulatory approvals and the pursuit of capital. The year-over-year EPS (TTM) trend captures these financial fluctuations, where the -58.80 level serves as a critical benchmark. The integration of nanoparticles into standard therapy promises a steady revenue stream, while management's flexible strategy in partnership with a pharma behemoth increases the likelihood of successful clinical trials.

Nanobiotix S.A. (NBTX) - Net earnings per share (EPS TTM) from 02/11/2024 to 11/18/2026

Nanobiotix Corp - analytical breakdowns and key metrics (NBTX)

- current price and projected stock value:
Initial company analysis:NBTX, Nanobiotix SA
Manufactured products of Nanobiotix SA

This indicator measures the dynamics of net earnings per share over a rolling year, neutralizing quarterly gaps and capturing the business's operational response to market changes. For Nanobiotix S.A. (NBTX), which depends on FDA/EMA approvals and currently lacks active patients, the YoY change in EPS on a rolling 12-month basis serves as a marker of financial stability during the pre-commercialization phase supported by J&J.